IGFBP4 and systemic sclerosis: Since our data demonstrate IGFBP‐4 has antifibrotic activity, we measured IGFBP‐4 mRNA levels in primary fibroblasts from lung tissues of patients with SSc‐associated pulmonary fibrosis.